King of Prussia, PA – September 26, 2023 – NanoCell Therapeutics, Inc. (“NanoCell”) is pleased to announce the appointment of Dr. Jacek Lubelski as its new Chief Technology Officer (CTO), effective immediately. Dr. Lubelski brings over a decade of experience in the biopharmaceutical industry and is recognized for his pioneering work in gene therapy technologies, particularly in recombinant adeno-associated virus (rAAV) therapeutics.
Prior to joining NanoCell, Dr. Lubelski served as the VP of Pharmaceutical Development at UniQure NV (NASDAQ: QURE). During his tenure, he contributed to the development of multiple rAAV-based advanced therapy medicinal products (ATMPs) to address complex diseases, such as Haemophilia B, and Huntington disease. Dr. Lubelski was involved in obtaining market authorization for Glybera, a groundbreaking gene therapy medicine for lipoprotein lipase (LPL) deficiency and most recently Hemgenix.
His leadership extended to overseeing vector development, process development, analytical methods, pre-clinical studies, and CMC activities, resulting in significant advancements in viral vector manufacturing platforms. As CTO, Dr. Lubelski will lead strategic technology initiatives, drive innovation in gene and cell therapy, and reinforce NanoCell Therapeutics’ position as a pioneering force in the biotech sector.
Maurits W. Geerlings, President and CEO of NanoCell Therapeutics, remarked, “Under Jacek’s guidance, NanoCell Therapeutics is poised to continue advancing the frontiers of gene and cell therapy. His expertise and dedication will be instrumental in our pursuit of cutting-edge solutions for patients worldwide.”
Dr. Lubelski holds a Ph.D. in Molecular Microbiology from the University of Groningen and a master’s degree in biotechnology from Maria Curie-Sklodowska University in Lublin, Poland. He is currently pursuing eMBA studies at the Rotterdam School of Management, Erasmus University in Rotterdam, the Netherlands.
Dr. Lubelski expressed his enthusiasm for his new role, stating, “I’m excited to step into the position of Chief Technology Officer at NanoCell Therapeutics. We have the potential to drive transformative advancements in gene and cell therapy, and I look forward to leading our outstanding scientific team to achieve these goals.”
About NanoCell Therapeutics, Inc.
NanoCell Therapeutics is a privately-held biotechnology company with offices in King of Prussia, Pennsylvania, and Utrecht, the Netherlands. Our mission is to revolutionize in-vivo cell engineering through our groundbreaking non-viral, DNA-based gene therapy platform, primarily focusing on oncology and autoimmune diseases. At NanoCell, we’re driving innovation by transforming traditional adoptive cell therapy methods into advanced in-vivo treatments. Our ultimate goal is to simplify the treatment process, increasing patient accessibility, potential clinical benefits, and cost-effective manufacturing. We work both autonomously and in collaboration with partners to make substantial advancements in our targeted disease areas. For more information, please visit our website at http://www.nanocelltx.com.
Investor & Media Contact:
Aisha Lindman, MBA
+31 (0) 70 3643095